Research programme: cyclophilin inhibitors - NeuroVive

Drug Profile

Research programme: cyclophilin inhibitors - NeuroVive

Alternative Names: BC 556; nPT-CyP; NV 556; NVP 018; NVP 024; NVP 025; NVP-022; NVP018/BC556; OCB-030; Sangamides

Latest Information Update: 09 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biotica Technology
  • Developer Arbutus Biopharma; Karolinska Institute; NeuroVive Pharmaceutical
  • Class Macrolides
  • Mechanism of Action Cyclophilin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Non-alcoholic steatohepatitis

Highest Development Phases

  • Preclinical Hepatocellular carcinoma; Non-alcoholic steatohepatitis
  • Research Mitochondrial myopathies
  • Discontinued Hepatitis B; Hepatitis C

Most Recent Events

  • 18 May 2017 NeuroVive Pharmaceuticals and Karolinska University Hospital enter a research collaboration to develop NVP 025 for Mitochondrial myopathy
  • 22 Feb 2017 NeuroVive enters into a research collaboration with The Scripps Research Institute to explore the mechanisms of action of sanglifehrin-based cyclophilin inhibitors
  • 22 Feb 2017 NeuroVive Pharmaceutical in-licenses Engitix' human liver 3D models technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top